Volume 2.02 | Jan 18

Hematopoiesis News 2.02, January 18, 2011.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Vascular Endothelial Growth Factor and Fibroblast Growth Factor Prime Vascular Tube Morphogenesis and Sprouting Directed by Hematopoietic Stem Cell Cytokines 
Scientists demonstrate a novel, direct acting, and synergistic role for three hematopoietic stem cell cytokines, stem cell factor, interleukin-3 and stromal derived factor-1, in controlling human endothelial cell tube morphogenesis, sprouting, and pericyte-induced tube maturation under defined serum-free conditions in 3D matrices. [Blood]



Facebook Cell Therapy News is now on Facebook! Join us.

Twitter Follow us on Twitter! @Hema_News

Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at [email protected]


ACT’s Joint Venture Reports Embryonic Stem Cells are a Potentially Unlimited Source of Functional Platelets for Transfusion
Advanced Cell Technology, Inc. (ACT) reported that its hemangioblast-based technology can be used to generate functional platelets from human embryonic stem cells (hESCs). This research shows that it is feasible to generate functional megakaryocytes and platelets from hESCs on a large scale. [Press release from Stem Cell & Regenerative Medicine International, Inc. discussing online prepublication in Cell Research]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


HDAC11 Plays an Essential Role in Regulating OX40 Ligand Expression in Hodgkin Lymphoma
Scientists investigated whether histone deacetylase inhibitors may induce a favorable antitumor immune response by regulating the expression of OX40 ligand in Hodgkin lymphoma. [Blood]

Normal Bone Marrow Signal Transduction Profiles: A Requisite for Enhanced Detection of Signaling Dysregulations in AML
Molecular and cytogenetic alterations are involved in virtually every facet of acute myeloid leukemia (AML) cell transformation including dysregulation of major signal transduction pathways. The present study examines five phospho-proteins pErk, pAkt, pS6, pStat3 and pStat5 in response to five cytokine/growth factors (SCF, FL, GM-CSF, IL-3, G-CSF) within seven immunophenotypically defined populations, spanning progenitor to mature myeloid/myelomonocytic cells in 11 normal adult bone marrows with further comparison to 12 AML samples. [Blood]

Rumba and Haus3 are Essential Factors for the Maintenance of Hematopoietic Stem/Progenitor Cells during Zebrafish Hematopoiesis
Investigators report the isolation and characterization of two zebrafish mutants, rumbahkz1 and sambahkz2, that are defective in generating definitive hematopoiesis. [Development]

Platelets Generated from Human Embryonic Stem Cells Are Functional In Vitro and in the Microcirculation of Living Mice
Scientists report that it is feasible to generate functional megakaryocytes and platelets from human embryonic stem cells on a large scale. [Cell Res]

Mad2 Haploinsufficiency Protects Hematopoietic Progenitor Cells Subjected to Cell Cycle Stress In Vivo and to Inhibition of Redox Function of Ape1/Ref-1 In Vitro
Researchers evaluated effects of mititotic arrest deficiency 2 (Mad2) haploinsufficiency on hematopoietic stem and progenitor function in response to stress. [Exp Hematol]

GSK-3Beta Negatively Regulates Megakaryocyte Differentiation and Platelet Production from Primary Human Bone Marrow Cells In Vitro
In the present study, primary human bone marrow cells were cultured for 12 days in megakaryocyte lineage induction media to induce their differentiation into megakaryocyte (MK) lineage cells, in the presence or absence of TWS119, a glycogen synthase kinase (GSK)-3beta inhibitor, during MK differentiation from stem cells and subsequent platelet production. [Platelets]


Hematopoietic Cell Transplantation Comorbidity Index Predicts Transplant Outcomes in Pediatric Patients
Scientists conducted a retrospective cohort study of 252 pediatric patients undergoing their first allogeneic hematopoietic cell transplantation between January 2008 and May 2009. [Blood]

Allogeneic Hematopoietic Stem Cell Transplantation in Leukocyte Adhesion Deficiency Type 1: A Single Center Experience
A retrospective analysis was performed for eleven patients diagnosed with leukocyte adhesion deficiency type-1 who underwent hematopoietic stem cell transplantations over the past 19 years at a single institution. [Biol Blood Marrow Transplant]

T-Cell Depleted Unrelated Donor Stem Cell Transplantation Provides Favorable Disease-Free Survival for Adults with Hematologic Malignancies
Researchers report a prospective Phase II clinical trial in 35 adult patients (median age 40.5 years) with hematologic malignancies who received T-cell depleted, hematopoietic stem cell transplants from HLA-compatible, unrelated donors. [Biol Blood Marrow Transplant]

Comparison Between Matched Related and Alternative Donors of Allogeneic Hematopoietic Stem Cells Transplanted into Adult Patients with Acquired Aplastic Anemia: Multivariate and Propensity Score-Matched Analysis
Investigators retrospectively compared the outcomes of 225 patients with adult acquired aplastic anemia who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT) from matched related donors, and those treated by alloHSCT from alternative donors. [Biol Blood Marrow Transplant]

Pre-Transplant Consolidation Chemotherapy May Not Improve Outcomes After Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
Scientists reviewed 60 consecutive patients with acute myeloid leukemia in CR1 undergoing reduced-intensity hematopoietic stem cell transplantation at the University of Minnesota and evaluated outcomes based on exposure to pre-transplant consolidation chemotherapy. [Leuk Res]



Cyclacel Begins Pivotal Phase III “SEAMLESS” Trial of Sapacitabine as Front-Line Treatment for AML Under a Special Protocol Assessment
Cyclacel Pharmaceuticals, Inc. announced that it has opened enrollment of the SEAMLESS pivotal Phase III trial for the Company’s sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy. [Cyclacel Pharmaceuticals, Inc. Press Release]

ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
ADVENTRX Pharmaceuticals, Inc. announced that it has signed a term sheet to acquire a private company that holds certain rights and know-how to poloxamer-based therapeutics. [ADVENTRX Pharmaceuticals, Inc. Press Release]

AACR Recognizes the Outstanding Achievements of Pier Paolo Pandolfi
Pier Paolo Pandolfi, M.D., Ph.D., is the recipient of the 2011 Pezcoller Foundation-AACR International Award for Cancer Research for his outstanding work in the field of cancer genetics and mouse models for cancer. [American Association for Cancer Research (AACR) Press Release]

Bayer HealthCare Marks Opening of U.S. Innovation Center 
Bayer HealthCare announced that its pharmaceutical division has established a master agreement for research collaborations with the University of California, San Francisco. [Bayer HealthCare Press Release]

Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us